Congratulations to CMMPH Professor Edwin van Teijlingen on his latest publication about why researchers do not always seek ethical permission for health research conducted in low income countries. The authors in this paper have identified and explained five possible reasons; a) approval not needed: b) not familiar with the ethics committee: c) applying the wr
ong committee; d) resource constraints; and e) assumption that non-clinical research are exempted, which are of course overlap and interact each other, for not applying ethical approval in low income countries. They have also provided examples of ethical approval taken from other countries than the host countries and further go on to stress that junior researchers and students should be encouraged to be familiar with research ethical approval. In their paper, they encourage journal editors and peer reviewers to ensure ethical approval bein
g granted for manuscripts based on empirical studies. This paper was co-authored by BU visiting faculty Professor Padam Simkhada and recently published in Nepal Journal of Epidemiology. The paper is freely available through the journal’s website http://nepjol.info/index.php/NJE/issue/view/919
Reference:
van Teijlingen E, Simkhada P. Failure to apply for ethical approval for health studies in low-income countries. Nepal J Epidemiol. 2015;5(3); 511-515
Pramod R Regmi, PhD
Post Doctoral Research Fellow, Faculty of Health and Social Science














Register now to attend the 17th Annual Postgraduate Research Conference – Wednesday 3 December 2025
Portrait Concert featuring BU academic at L’Espace du Son Festival 2025, Brussels
From Clinical Applications to Neuro-Inspired Computation
ECR Funding Open Call: Research Culture & Community Grant – Application Deadline Friday 12 December
MSCA Postdoctoral Fellowships 2025 Call
ERC Advanced Grant 2025 Webinar
Horizon Europe Work Programme 2025 Published
Horizon Europe 2025 Work Programme pre-Published
Update on UKRO services
European research project exploring use of ‘virtual twins’ to better manage metabolic associated fatty liver disease